- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT01042925
Study of XL147 (SAR245408) in Combination With Trastuzumab or Paclitaxel and Trastuzumab in Subjects With Metastatic Breast Cancer Who Have Progressed on a Previous Trastuzumab-based Regimen
A Phase 1/2 Study of XL147 (SAR245408) Administered in Combination With Trastuzumab or Paclitaxel and Trastuzumab in Subjects With Metastatic Breast Cancer Who Have Progressed on a Previous Trastuzumab-Based Regimen
Phase 1 of this study will evaluate the maximum tolerated dose (MTD) of XL147 when given in combination with trastuzumab (Herceptin) and in combination with trastuzumab and paclitaxel. After the MTD is established for each combination (Phase 2), subjects will be enrolled to evaluate the preliminary efficacy and safety of these combinations in metastatic HER2 positive breast cancer. Both trastuzumab and paclitaxel are used in the treatment of metastatic breast cancer (MBC), but patients can develop resistance.
The link between PI3K mutations and trastuzumab resistance has been seen in breast cancer patients. This suggests that inhibitors of the PI3K/PTEN pathway may have the potential to restore sensitivity to trastuzumab. Similarly, introduction of activated mutant forms of PI3K has been shown to transform and confer paclitaxel resistance to immortalized breast epithelial cells. XL147 is a potent and selective inhibitor of PI3K and inhibits phosphorylation of multiple downstream components of PI3K/PTEN signaling. Therefore, XL147 may have utility in the treatment of trastuzumab resistant/refractory and HER2-positive MBC when administered in combination with trastuzumab alone or with trastuzumab and paclitaxel.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Faktiske)
Fase
- Fase 2
- Fase 1
Kontakter og plasseringer
Studiesteder
-
-
California
-
Los Angeles, California, Forente stater, 90033
- Investigational Site Number 1537
-
-
Florida
-
Fort Meyers, Florida, Forente stater, 33901
- Investigational Site Number 1238
-
-
Massachusetts
-
Boston, Massachusetts, Forente stater, 02115
- Investigational Site Number 1138
-
-
Michigan
-
Detroit, Michigan, Forente stater, 48201
- Investigational Site Number 1330
-
-
New York
-
Bronx, New York, Forente stater, 10467
- Investigational Site Number 1151
-
New York, New York, Forente stater, 10032
- Investigational Site Number 1150
-
-
Tennessee
-
Nashville, Tennessee, Forente stater, 37203
- Investigational Site Number 1214
-
Nashville, Tennessee, Forente stater, 37232
- Investigational Site Number 1246
-
-
-
-
-
Madrid, Spania, 28041
- Investigational Site Number 3413
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- The subject has pathologically and radiologically confirmed metastatic HER2 positive breast cancer (Stage IV disease). Subjects must have received and progressed on at least one prior trastuzumab-containing regimen for metastatic disease. For subjects in Arm 2, they must also have received at least one prior taxane-containing regimen.
- The subject has at least one lesion that is not within a previously radiated field and measurable on computerized tomography (CT) or magnetic resonance imaging scan (MRI)
- The subjects enrolled in Phase 2 must be willing to undergo a biopsy of the primary tumor or a tumor metastasis at baseline, if tumor tissue is amenable to biopsy
- The subject's primary tumor and/or metastatic lesion must overexpress HER2
- For subjects enrolled in Phase 2: samples from archival or fresh tissue, or a tissue block of the subject's tumor.
- The subject has an Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2
- The subject has adequate organ and marrow function
- The subject is capable of understanding the informed consent and complying with the protocol and has signed the informed consent document prior to any study-specific screening procedures or evaluations being performed.
- Sexually active subjects must agree to use a medically-accepted barrier method of contraception during the course of the study and for 3 months following discontinuation of study treatments. For subjects using oral contraceptives, a barrier method must be used in addition to the oral contraceptive
- Subjects of childbearing potential must have a negative pregnancy test at screening and enrollment
Exclusion Criteria:
- The subject has previously been treated with a selective inhibitor of PI3K and / or AKT
- Certain restrictions on prior therapies apply
- The subject has not recovered from toxicity due to prior therapy to Grade ≤ 1 or to pre-therapy baseline
- The subject has untreated, symptomatic, or progressive brain metastases. Any corticosteroid use for brain metastases must have been discontinued without the subsequent appearance of symptoms for ≥4 weeks prior to first study treatment
- The subject has prothrombin time/International Normalized Ratio (PT/INR) or partial thromboplastin time (PTT) test results at screening that are ≥ 1.3 times above the laboratory upper limit of normal
- The subject has a diagnosis of uncontrolled diabetes mellitus
- The subject has uncontrolled significant intercurrent illness
- The subject has uncontrolled hypertension or other clinically significant cardiovascular disease
- The subject has left ventricular ejection fraction (LVEF) ≤ 50%
- The subject has a baseline corrected QT interval ≥ 460 ms
- The subject is currently receiving anticoagulation with therapeutic doses of warfarin (low-dose warfarin ≤ 1mg/day is permitted)
- The subject is pregnant or breastfeeding
- The subject is known to be positive for the human immunodeficiency virus (HIV) (a test for HIV at screening is not required)
- The subject has any other diagnosis of malignancy or evidence of malignancy (except non-melanoma skin cancer, in situ carcinoma of the cervix) within 2 years prior to screening for this study
- The subject has a previously identified allergy or hypersensitivity or is intolerant to components of any of the study treatment formulations
- The subject is unable or unwilling to abide by the study protocol or cooperate fully with the investigator or designee
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Eksperimentell: Arm 1
XL147 in combination with trastuzumab
|
administered orally once daily as tablet(s)
administered by IV once every 3 weeks
Andre navn:
|
Eksperimentell: Arm 2
XL147 in combination with trastuzumab and paclitaxel
|
administered orally once daily as tablet(s)
administered by IV once every 3 weeks
Andre navn:
administered by IV once every week
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
---|---|
Safety and tolerability of XL147 in combination with trastuzumab and in combination with trastuzumab and paclitaxel
Tidsramme: safety assessments at weekly study visits
|
safety assessments at weekly study visits
|
In Phase 1, the maximum tolerated dose (MTD) of XL147 when administered in combination with trastuzumab and in combination with trastuzumab and paclitaxel
Tidsramme: assessed by weekly study visits
|
assessed by weekly study visits
|
In Phase 2, objective tumor response
Tidsramme: every 6 weeks
|
every 6 weeks
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
---|---|
Duration of response and progression-free survival (Phase 2)
Tidsramme: every 6 weeks
|
every 6 weeks
|
Pharmacokinetics and pharmacodynamics of XL147 and trastuzumab when given in combination, and of XL147, trastuzumab, and paclitaxel when given in combination
Tidsramme: assessed weekly, then every 3 weeks
|
assessed weekly, then every 3 weeks
|
Samarbeidspartnere og etterforskere
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Hudsykdommer
- Neoplasmer
- Neoplasmer etter nettsted
- Bryst sykdommer
- Brystneoplasmer
- Molekylære mekanismer for farmakologisk virkning
- Antineoplastiske midler
- Tubulin modulatorer
- Antimitotiske midler
- Mitosemodulatorer
- Antineoplastiske midler, fytogene
- Antineoplastiske midler, immunologiske
- Paklitaksel
- Trastuzumab
Andre studie-ID-numre
- ARD11439
- XL147-203 (Annen identifikator: (other study code))
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Brystkreft
-
Tianjin Medical University Cancer Institute and...Guangxi Medical University; Sun Yat-sen University; Chinese PLA General Hospital og andre samarbeidspartnereFullførtThe Clinical Application Guide of Conebeam Breast CTKina
-
Novartis PharmaceuticalsFullførtMetastatisk brystkreft (MBC) | Locally Advance Breast Cancer (LABC)Storbritannia, Spania
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.UkjentHR-positiv, HER2-negativ og PIK3CA Mutation Advanced Breast CancerKina
-
Emory UniversityNational Cancer Institute (NCI)TilbaketrukketPrognostisk stadium IV brystkreft AJCC v8 | Metastatisk malign neoplasma i hjernen | Metastatisk brystkarsinom | Anatomic Stage IV Breast Cancer American Joint Committee on Cancer (AJCC) v8
-
NRG OncologyNational Cancer Institute (NCI)Aktiv, ikke rekrutterendeAnatomisk stadium IV brystkreft AJCC v8 | Prognostisk stadium IV brystkreft AJCC v8 | Metastatisk malign neoplasma i beinet | Metastatisk malign neoplasma i lymfeknutene | Metastatisk malign neoplasma i leveren | Metastatisk brystkarsinom | Metastatisk malign neoplasma i lungen | Metastatisk malign neoplasma... og andre forholdForente stater, Canada, Saudi-Arabia, Korea, Republikken
Kliniske studier på XL147 (SAR245408)
-
SanofiFullførtEndometriale neoplasmer | LivmorkreftForente stater, Belgia
-
SanofiFullførtLymfom | KreftForente stater, Spania
-
SanofiFullførtSolide svulsterForente stater
-
SanofiFullførtGlioblastom | Astrocytom, grad IVForente stater
-
SanofiFullførtKreft | Ikke-småcellet lungekreft | Endometriekarsinom | OvariekarsinomForente stater
-
SanofiFullført
-
SanofiFullførtNeoplasma ondartetJapan
-
SanofiFullførtBrystkreftForente stater, Frankrike, Spania
-
SanofiFullførtNeoplasma ondartetSpania, Belgia, Forente stater, Frankrike
-
SanofiMerrimack PharmaceuticalsFullførtSolid svulstkreftForente stater